Written Asthma Actions Plans Versus No Written Instructions In Specialty Care
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||The Efficacy of Written Treatment Plans in Asthma|
- Reduction in asthma symptom frequency [ Time Frame: Measured at 3 month intervals for 12 months ]Using a 2-week recall period, asthma symptom frequency was measured in 3 ways: (a) the average number of days with asthma symptoms; (b) the average number of nights with symptoms; and (c) the average number of days the participant used a short-acting bronchodilator.
- Reduction in urgent, unscheduled, and emergency visits for asthma [ Time Frame: Measured at 3 month intervals for 12 months ]Emergency, urgent, and unscheduled visits for asthma were combined into a single measure and assessed using a 3-month recall.
- Improved quality of life [ Time Frame: Measured at 6 and 12 months ]Asthma QOL, using the Juniper Mini Asthma QOL Scale (MiniAQLQ) for adult participants and the Juniper Pediatric Asthma Caregivers QOL Questionnaire (PACQLQ) for parents, was assessed at 6 and 12-months follow-up.
- Hospitalizations due to asthma [ Time Frame: Measured at 3 month intervals for 12 months ]Assessed the number of hospital admissions over the previous 3 months.
- Days with activity restriction [ Time Frame: Measured at 3 month intervals for 12 months ]Days with activity limitations were defined as the number of days missed from school or work due to asthma.
- Proportion of participants in the intervention group who are given the written asthma action plan form during the initial visit [ Time Frame: Measured at the exit interview after the initial visit with the specialist physician ]Participants in each group show the research assistant all written materials they received from the physician during the visit.
- Proportion of patients in the intervention group who have the model treatment plan at the end of the follow-up period [ Time Frame: Measured at 12 month interview ]Assessed retention of the written asthma action plan (WAAP) by asking participants to read a specific line from the written asthma action plan to demonstrate that they had the WAAP in their possession.
|Study Start Date:||September 2006|
|Study Completion Date:||July 2009|
|Primary Completion Date:||April 2008 (Final data collection date for primary outcome measure)|
Experimental: Written Asthma Action Plan Group
Participants randomized to the written asthma action plan group received an asthma action plan form along with asthma education from their specialist physician.
Behavioral: Written Asthma Action Plan
No Intervention: No Written Instructions Group
Participants randomized to the usual care group received no written instructions other than prescriptions from their specialist physician.
Effective self-management of asthma requires that patients, or their caregivers, recognize the early symptoms of an exacerbation and initiate appropriate interventions aimed at preventing the progression of symptoms. Most asthma clinical guidelines suggest that the incorporation of a written self-management plan is essential. Patients must possess, understand, and follow a written plan if they are to respond appropriately to changes in asthma status. Nevertheless, there are no controlled studies examining the efficacy of the written plan itself. Furthermore, even if written plans are an essential and effective component of successful self-management, the data suggest that few patients receive these plans. If patients and physicians are to increase their use of written plans, the barriers to the use of these plans need further investigation.
The three primary outcome measures of this study are as follows: 1) reduction in asthma symptom frequency; 2) reduction in urgent, unscheduled, and emergency visits for asthma; and 3) improved quality of life. These outcomes will be measured over a 12-month period.
The following four secondary outcome measures will also be examined: 1) hospitalizations due to asthma; 2) days with activity restriction; 3) the proportion of patients in the intervention group who are given the model written plan form during the initial visit; and 4) the proportion of patients in the intervention group who have the model treatment plan at the end of the follow-up period. These outcomes will be measured over a 12-month period.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00149461
|United States, New York|
|New York, New York, United States, 10032|
|Principal Investigator:||David Evans, PhD||Columbia University|